Detection of CTX-II in serum and urine to diagnose osteoarthritis by using a fluoro-microbeads guiding chip

Park, Yoo Min; Kim, Su Jin; Lee, Ki Jung; Yang, Sang Sik; Min, Byoung‐Hyun

doi:10.1016/j.bios.2014.08.016

Cited by 38 publications

(21 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[ 21 – 26 ] The CTX-II is released into the serum and urine, and the CTX-II concentration in body fluids reflects OA progression. [ 27 ] Studies showed that serum CTX-II can be used to monitor the OA progression. [ 28 ] CTX-II in urine can be used to diagnose and assess the osteoarthritis.…”

Section: Discussionmentioning

confidence: 99%

Comparative study of CTX-II, Zn2+, and Ca2+ from the urine for knee osteoarthritis patients and healthy individuals

Xin

et al. 2017

Medicine

View full text Add to dashboard Cite

The aim of the study was to explore the relationship between the concentration of C-telopeptide fragments of type II collagen (CTX-II), Zn2+, and Ca2+ in urine and knee osteoarthritis (KOA).Eighty-two patients with KOA and 20 healthy volunteers were enrolled. Anteroposterior and lateral position x-rays of knee joints were collected. The images were classified according to Kellgren-Lawrence radiographic grading criterion. The patients were divided into group grade I, group grade II, group grade III, and grade IV. The concentration of CTX-II in the urine was detected by enzyme-linked immunosorbent assay. The concentration of Zn2+ and Ca2+ in urine was detected by inductively coupled plasma atomic emission spectrometry.Compared with the healthy individuals, the concentration of CTX-II was significantly higher in KOA patients. The concentration of CTX-II in KOA patients from high to low was as follows: group IV, group III, group II, and group I. There was no significant difference between group I and healthy individuals. The concentration of Zn2+ and Ca2+ in urine of KOA patients was higher than that in healthy individuals. There was no difference in each KOA group.The concentration of CTX-II is instrumental to diagnose the progress of KOA. The concentration of Zn2+ and Ca2+ in urine is helpful for early diagnosis of KOA.

show abstract

Section: Discussionmentioning

confidence: 99%

Comparative study of CTX-II, Zn2+, and Ca2+ from the urine for knee osteoarthritis patients and healthy individuals

Xin

et al. 2017

Medicine

View full text Add to dashboard Cite

show abstract

“…CTX-II detection is possible not only in the urine but also in serum by various methods, like enzyme immunoassays or fluorescent beads-based chip techniques. 90 In a chemically generated rat OA model, we observed that s-CTX-II is suppressed significantly by meloxicam treatment even 4 weeks after stopping the therapy. 91 Luo et al argue for the non-comparable value of the two markers: examining 227 participants of the C4Pain Study they observed that only u-CTX-II could be significantly correlated to the WOMAC scores.…”

Section: Collagen Type II Degradation Products and Comp As Biomarkersmentioning

confidence: 81%

<p>Soluble Biomarkers of Osteoporosis and Osteoarthritis, from Pathway Mapping to Clinical Trials: An Update</p>

Nagy

Nagy-Finna

Popoviciu

et al. 2020

CIA

View full text Add to dashboard Cite

Serum biomarkers of osteoarticular diseases have been in the limelight of current clinical research trends. Laboratory validation of defined and candidate biomarkers for both osteoarthritis and osteoporosis is of key importance for future decisional algorithms in the diagnosis, monitoring, and prognosis of these diseases. The current guidelines recommend the use of collagen degradation remnants, eg, CTX-I and CTX-II, in the complementary diagnosis of both osteoporosis and osteoarthritis. Besides the collagen degradation markers, enzymes that regulate bone and articular metabolism are useful in the clinical evaluation of osteoarticular pathologies. Along these, several other recommended and new nominee molecules have been recently studied. Wnts and Wnt-related molecules have a cardinal role in the bone-joint homeostasis, making them a promising target not only for pharmaceutical modulation, but also to be considered as soluble biomarkers. Sclerostin and dickkopf, two inhibitor molecules of the Wnt/β-catenin signaling, might have a dual role in the assessment of the clinical manifestations of the osteoarticular unit. In osteoarthritis, besides fragments of collagen type II many pathway-related molecules have been studied and proposed for biomarker validation. The most serious limitation is that a significant proportion of studies lack statistical power due to the reduced number of cases enrolled. Serum biomarkers of bone and joint turnover markers represent an encouraging possibility for the diagnosis and prognosis of osteoarticular diseases, although further studies and laboratory validations should be carried out as to solely rely on them.

show abstract

“…Thus, measurements of fragments derived from this protein may potentially represent a specific marker for cartilage degradation. Previous studies reported that the concentrations of CTX-II in urine and serum reveal the extent of cartilage damage and are a good marker of OA progression [ 10 – 13 ]. The FYC could protect the collagen and proteoglycan of the articular cartilage in a rat OA model in the current study.…”

Section: Discussionmentioning

confidence: 99%

Chondroprotective Effects and Multitarget Mechanisms of Fu Yuan Capsule in a Rat Osteoarthritis Model

Zeng

Xiao

Deng

et al. 2017

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Fu Yuan Capsule (FYC) has been clinically used for osteoarthritis (OA) and its related diseases for many years in China. However, its pharmacological mechanism remains unclear. This study aimed to investigate the potential chondroprotective effects of FYC on articular cartilage. Rat OA model was induced by anterior cruciate ligament transection. A group of rats was treated with FYC for 12 weeks. Joint structure, types I and II collagen, and proteoglycan were evaluated by histological examination. The expression of C-terminal crosslinking telopeptide of type II collagen, hydroxyproline, a disintegrin and metalloproteinase with thrombospondin motifs, matrix metalloproteinase, interleukin-1 beta, nitric oxide, prostaglandin E2, heat-shock protein 70, transforming growth factor-beta, osteoprotegerin, and receptor activator of nuclear factor κB ligand were detected. Treatment with FYC could protect against articular cartilage injury. FYC treatment significantly decreased the extracellular matrix degradation factors and inflammatory mediators. Moreover, articular cartilage protective factors were increased in the FYC group. The current finding suggests that FYC protects articular cartilage in a rat OA model through various ways. Thus, it may be an effective agent for OA treatment.

show abstract

Detection of CTX-II in serum and urine to diagnose osteoarthritis by using a fluoro-microbeads guiding chip

Cited by 38 publications

References 30 publications

Comparative study of CTX-II, Zn2+, and Ca2+ from the urine for knee osteoarthritis patients and healthy individuals

Comparative study of CTX-II, Zn2+, and Ca2+ from the urine for knee osteoarthritis patients and healthy individuals

<p>Soluble Biomarkers of Osteoporosis and Osteoarthritis, from Pathway Mapping to Clinical Trials: An Update</p>

Chondroprotective Effects and Multitarget Mechanisms of Fu Yuan Capsule in a Rat Osteoarthritis Model

Contact Info

Product

Resources

About